Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Asthma genetics: personalizing medicine.

Warrier MR, Hershey GK

Institute for Personalized and Predictive Medicine and Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA. Gurjit.Hershey@chmcc.org

Asthma is a chronic inflammatory lung disease that leads to significant morbidity, mortality, and economic burden. The clinical symptoms, which are a result of airway inflammation and reversible airway obstruction, have led to the mainstay of therapies for asthma: anti-inflammatory medications and bronchodilators. However, the efficacies of the various classes of medications are not equal among all patients and may be affected by asthma phenotypes, environmental exposures, and genetic differences. Similarly, the risk for developing asthma and the natural history of the disease show great inter-individual variability due to these same factors. Over the past few decades, much effort has been focused on the genetics of asthma, and investigators have identified more than one hundred potential asthma susceptibility genes, of which at least ten have been replicated in numerous independent studies. In parallel, researchers have also identified genetic factors that impact the pharmacotherapeutic responses to the major classes of asthma medications. While the results of previous studies have been promising, future investigations need to combine genetics, pharmacogenetics, accurate disease phenotyping, and environmental exposures to build the foundation for personalized and predictive medicine for the 21st century. The ultimate goal is to enable physicians to identify those at risk for asthma, intervene to prevent or attenuate the disease, and select the optimal medical regimen for each individual patient. If successful, the resulting paradigm shift in medical practice will lead to improved clinical outcomes and decreased health care expenditures.

Published 30 April 2008 in J Asthma, 45(4): 257-64.
Full-text of this article is available online (may require subscription).

Articles on Pharmacology published 25 April 2008:

Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.   Science, 320(5875): 520-3.

beta-Secretase plays a critical role in beta-amyloid formation and thus provides a therapeutic target for Alzheimer's disease. Inhibitor design has usually focused on active-site binding, neglecting the subcellular localization of active enzyme. We have addressed this issue by synthesizing a membrane-anchored version of a beta-secretase transition-state inhibitor by linking it to a sterol moiety. Thus, we targeted the inhibitor to active beta-secretase found in endosomes and also reduced the ... [Abstract] [Full-text]

Articles on Pharmacology published 21 April 2008:

India takes an open source approach to drug discovery.   Cell, 133(2): 201-3.

Open source software may have been around for 17 years, but using an open source model to speed up drug discovery is a relatively new idea. This month, India is launching a new open source initiative for developing drugs to treat diseases such as tuberculosis, malaria, and HIV. [Abstract] [Full-text]

Pharmacogenetics: from bench to byte.   Clin Pharmacol Ther, 83(5): 781-7.

Despite initial enthusiasm, the use of pharmacogenetics has remained limited to investigation in only a few clinical fields such as oncology and psychiatry. The main reason is the paucity of scientific evidence to show that pharmacogenetic testing leads to improved clinical outcomes. Moreover, for most pharmacogenetic tests (such as tests for genetic variants of cytochrome P450 enzymes) a detailed knowledge of pharmacology is a prerequisite for application in clinical practice, and both ... [Abstract] [Full-text]

Articles on Pharmacology published 3 April 2008:

Antimicrobial prescribing trends in primary care: implications for health policy in Bahrain.   Pharmacoepidemiol Drug Saf, 17(4): 389-96.

PURPOSE: To evaluate antimicrobial prescribing pattern by primary care physicians. METHODS: A nation-wide, retrospective, multi-centric prescription-audit was carried out in primary care health centres in Bahrain. RESULTS: Systemic antimicrobials ranked the fourth most common class of drugs prescribed. Amoxycillin, cephalexin, erythromycin, ciprofloxacin and cotrimoxazole were prescribed by general practitioners (GPs) more often than by family physicians (FPs) (p < 0.05). With respect to ... [Abstract] [Full-text]

Using prescription registries to define continuous drug use: how to fill gaps between prescriptions.   Pharmacoepidemiol Drug Saf, 17(4): 384-8.

Pharmacoepidemiological studies often use prescription registries to assess patients' drug episodes. The databases usually provide information on the date of the redemption of the prescription as well as on the dispensed amount, and this allows us to define episodes of drug use. However, when patients take less medication than prescribed, apparent gaps between prescriptions occur, and most studies handle this issue by allowing for small gaps when defining continuous drug use. This paper argues ... [Abstract] [Full-text]

Articles on Pharmacology published 2 April 2008:

Structural diversity of G protein-coupled receptors and significance for drug discovery.   Nat Rev Drug Discov, 7(4): 339-57.

G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and also the targets of many drugs. Understanding of the functional significance of the wide structural diversity of GPCRs has been aided considerably in recent years by the sequencing of the human genome and by structural studies, and has important implications for the future therapeutic potential of targeting this receptor family. This article aims to provide a comprehensive overview of the five main human ... [Abstract] [Full-text]

Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy.   Nat Rev Drug Discov, 7(4): 293-305.

In preclinical and early clinical drug development, information about the factors influencing drug disposition is used to predict drug interaction potential, estimate and understand population pharmacokinetic variability, and select doses for clinical trials. However, both in vitro drug metabolism studies and pharmacogenetic association studies on human pharmacokinetic parameters have focused on a limited subset of the proteins involved in drug disposition. Furthermore, there has been a one-way ... [Abstract] [Full-text]

High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology.   Nat Rev Drug Discov, 7(4): 358-68.

Ion channels represent highly attractive targets for drug discovery and are implicated in a diverse range of disorders, in particular in the central nervous and cardiovascular systems. Moreover, assessment of cardiac ion-channel activity of new chemical entities is now an integral component of drug discovery programmes to assess potential for cardiovascular side effects. Despite their attractiveness as drug discovery targets ion channels remain an under-exploited target class, which is in large ... [Abstract] [Full-text]

© 2005-2008 Pharmacology Research Today. All Rights Reserved.